Spanios is pleased to confirm the execution of a co-marketing agreement (the “Agreement”) with Inaphaea a UK based high throughput drug screening services using its Patient Derived Cells (“PDC”) as a precursor to Spanos’s proprietary Patient Derived Tumoroids (“PDT”).
Bhuvanesh Dave, PhD, Co-Founder and CEO of Spanios, commented “The partnership with Inaphaea is a perfect fit for our joint goal of accelerating drug development to bring therapies to patients faster. Combining Inaphaea’s higher throughput approach to candidate selection with our versatile three-dimensional PDT drug testing platform, COMPASS (Custom Organoid Modelling Platform for Accurate & Speedy Solutions) which is capable of recapitulating tumor microenvironment (TME) including features of oxygenation and immunocompetence, we can combine the best of both approaches for advancing discovery and development pipeline.”
Mark Eccleston, Director of Inaphaea BioLabs comments: “We are excited to be working with a highly innovative partner like Spanios. Bringing therapies to market faster requires better models for screening drugs to deliver more accurate and translatable results. Inaphaea has focussed on the early stage of this process where, typically, larger numbers of candidates need to be refined for screening in disease relevant models. We can then pass on the best candidates to Spanios for testing in their organoid platform.”
Read more about the agreement at Inaphaea Co-Marketing Agreement (eurolandir.com)
About Spanios
Spanios’s proprietary patient-derived 3D tumoroid (PDT) platforms bring patient diversity and biological complexity of solid tumors to therapeutic validation as well as to the earliest stages of drug discovery. The unique platform overcomes the limitations of traditional approaches such as xenografts and animal models by creating a resilient replica of host tumor environments with customizable testing conditions including variable levels of oxygenation and also immune-complemented. These models encompass both the tumor and its microenvironment growing together in unison to develop tumoroids that respond to treatments in a manner similar to that of the patient. This keeps the focus on identifying new pathways, bringing optimal treatments to the clinic, by enabling scientists to fast-track their search for novel cures to bring hope to millions of patients.
About ValiRx
ValiRx is a drug development company, which focuses on the translation of scientific innovation into clinical candidates for cancer, related conditions and women’s health. Our specialised business model connects science, finance and commerce to accelerate early-stage drug development.
We identify proprietary and novel drug candidates with the potential to improve patient lives, providing the expertise and investment required for optimised development and value creation.
ValiRx has been operating since 2000 and listed on the AIM Market of the London Stock Exchange in October 2006, trading under the ticker symbol: VAL.
For more information, please visit Drug Development – About ValiRx | ValiRx PLC
For more information:
Preethi Samuel PhD
Chief Operating Officer
Preethi.samuel@spanioslab.com
https://spanioslab.com
